| PESUB17 | DTG associated weight gain: real or perceived? Real world experiences from Zimbabwe | Poster exhibition | Weight gain |
| EPA069 | Dual antiretroviral loaded nanoparticles for long-acting suppressive HIV therapy | E-poster | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| EPD284 | Dual oral therapy in France (PROBI study): the acceptability of switch among HIV patients and physicians | E-poster | Behavioural factors impacting acceptability and uptake of an HIV vaccine |
| PESAA06 | Dual role of HIV-1 Envelope Signal Peptide in immune evasion | Poster exhibition | HIV transmission and dissemination |
| OAB0303 | Dual therapy based on DRVr plus 3TC in HIV-1 naïve patients: global 48 week results from ANDES Study | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| EPD035 | Dynamic considerations for acceptability and likely use of an MPT vaginal ring: a grounded theory model | E-poster | Qualitative and ethnographic methods in HIV research |
| EPC397 | Earlier HIV diagnosis of clients at higher CD4 counts: effectiveness of community-led HIV testing sites within key populations in Thailand | E-poster | HIV testing to support identification of new cases of people living with HIV |
| EPB035 | Early culture conversion among people with HIV and drug resistant tuberculosis in Uganda | E-poster | Tuberculosis: Prevention, diagnosis, treatment |
| EPB186 | Early implementation and clinical outcomes of long-acting injectable cabotegravir and rilpivirine in a safety-net HIV clinic | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPC472 | Early receipt of COVID-19 vaccines among people living with HIV: age, knowledge, and trust as determinants | E-poster | COVID-19 prevention |